G+FLAS’ headquarters is located in the Nakseongdae R & D Center near the Seoul National University and has a branch in Osong Hi-Tech Composite Medical Complex, Chungbuk. Moreover, G+FLAS has an affiliate corporation in the Purdue Research Park of the Purdue University, Indiana, USA.
G+FLAS is a technology-intensive global biotech startup company that develops genome editing application products with a total of 30 full-time researchers including 10 PhD scientists on site
Our mission and business model (or vision) is that "We can saves people's lives by producing biobetters for cancer immunotherapy using an efficient and more precise gene editing technology."

In 2012, we saw infinite possibilities with the CRISPR gene editing technology, which has been a revolutionary technology that mankind has never experienced before.
However, this gene editing technology still have a plenty of room for further improvement. The CRISPR does not always cut the target precisely, and as a result we canot ignore the off-target effects that cut the unintended locations. Before the development of an application of the technology, we are focusing on developing the CRISPR technology that can cut the targets more efficiently with a reduced amount of off-target effects. In the past two years, G+FLAS has developed 'CRISPR-PLUS ™' technology which has more than doubled the performance of the existing CRISPR technology on the market. In addition, we have also filed for the IP which quenches all further CRISPR activities to prevent unintended editing in the particular time.